• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲硫氨酸限制下 H3K4me3 和 H3K9me3 的组蛋白甲基化状态在甲硫氨酸成瘾性癌细胞中不稳定,但在正常细胞中稳定。

Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells.

机构信息

AntiCancer Inc, 7917 Ostrow St, San Diego, CA, 92111, USA; Department of Surgery, University of California, San Diego, 9300 Campus Point Drive #7220, La Jolla, CA, 92037-7220, USA; Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.

AntiCancer Inc, 7917 Ostrow St, San Diego, CA, 92111, USA.

出版信息

Biochem Biophys Res Commun. 2020 Dec 17;533(4):1034-1038. doi: 10.1016/j.bbrc.2020.09.108. Epub 2020 Oct 3.

DOI:10.1016/j.bbrc.2020.09.108
PMID:33019978
Abstract

Methionine addiction is a fundamental and general hallmark of cancer. Methionine addiction prevents cancer cells, but not normal cells from proliferation under methionine restriction (MR). Previous studies reported that MR altered the histone methylation levels in methionine-addicted cancer cells. However, no study has yet compared the status of histone methylation status, under MR, between cancer cells and normal cells. In the present study, we compared the histone methylation status between cancer cells and normal fibroblasts of H3K4me3 and H3K9me3, using recombinant methioninase (rMETase) to effect MR. Human lung and colon cancer cell lines and human normal foreskin fibroblasts were cultured in control medium or medium with rMETase. The viability of foreskin fibroblasts was approximately 10 times more resistant to rMETase than the cancer cells in vitro. Proliferation only of the cancer cells ceased under MR. The histone methylation status of H3K4me3 and H3K9me3 under MR was evaluated by immunoblotting. The levels of the H3K4me3 and H3K9me3 were strongly decreased by MR in the cancer cells. In contrast, the levels of H3K4me3 and H3K9me3 were not altered by MR in normal fibroblasts. The present results suggest that histone methylation status of H3K4me3 and H3K9me3 under MR was unstable in cancer cells but stable in normal cells and the instability of histone methylation status under MR may determine the high methionine dependency of cancer cells to survive and proliferate.

摘要

甲硫氨酸成瘾是癌症的一个基本和普遍特征。甲硫氨酸成瘾可阻止癌细胞在甲硫氨酸限制(MR)下增殖,但不能阻止正常细胞增殖。先前的研究报告称,MR 改变了甲硫氨酸成瘾癌细胞中的组蛋白甲基化水平。然而,尚无研究比较过 MR 下癌细胞和正常细胞之间的组蛋白甲基化状态。在本研究中,我们使用重组甲硫氨酸酶(rMETase)来实现 MR,比较了 H3K4me3 和 H3K9me3 之间的组蛋白甲基化状态在癌细胞和正常成纤维细胞之间的差异。将人肺癌和结肠癌细胞系和人正常包皮成纤维细胞在对照培养基或含 rMETase 的培养基中培养。体外 rMETase 对包皮成纤维细胞的存活率的抗性大约是癌细胞的 10 倍。只有癌细胞在 MR 下停止增殖。通过免疫印迹评估了 MR 下 H3K4me3 和 H3K9me3 的组蛋白甲基化状态。MR 强烈降低了 H3K4me3 和 H3K9me3 的水平。相比之下,MR 对正常成纤维细胞中的 H3K4me3 和 H3K9me3 水平没有影响。本研究结果表明,MR 下 H3K4me3 和 H3K9me3 的组蛋白甲基化状态在癌细胞中不稳定,而在正常细胞中稳定,MR 下组蛋白甲基化状态的不稳定性可能决定了癌细胞对甲硫氨酸的高依赖性,以维持生存和增殖。

相似文献

1
Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells.甲硫氨酸限制下 H3K4me3 和 H3K9me3 的组蛋白甲基化状态在甲硫氨酸成瘾性癌细胞中不稳定,但在正常细胞中稳定。
Biochem Biophys Res Commun. 2020 Dec 17;533(4):1034-1038. doi: 10.1016/j.bbrc.2020.09.108. Epub 2020 Oct 3.
2
Extent and Instability of Trimethylation of Histone H3 Lysine Increases With Degree of Malignancy and Methionine Addiction.组蛋白 H3 赖氨酸三甲基化的程度和不稳定性随恶性程度和蛋氨酸依赖性增加。
Cancer Genomics Proteomics. 2022 Jan-Feb;19(1):12-18. doi: 10.21873/cgp.20299.
3
Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation.在抑制甲硫氨酸成瘾性骨肉瘤细胞增殖的浓度下,重组蛋氨酸酶可降低组蛋白H3赖氨酸三甲基化标记物水平,而甲氨蝶呤则可使其升高。
Biochem Biophys Rep. 2021 Nov 26;28:101177. doi: 10.1016/j.bbrep.2021.101177. eCollection 2021 Dec.
4
Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylation.骨肉瘤细胞从甲硫氨酸成瘾状态转变为甲硫氨酸非依赖状态会导致恶性程度丧失、上皮-间质表型的调节以及组蛋白H3赖氨酸甲基化的改变。
Front Oncol. 2022 Nov 3;12:1009548. doi: 10.3389/fonc.2022.1009548. eCollection 2022.
5
Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.口服重组蛋氨酸酶与激动剂替加曲妥珠单抗联合应用可增加 TRAIL 受体-2 的表达,从而在原位小鼠模型中消退胰腺癌。
Cancer Lett. 2020 Nov 1;492:174-184. doi: 10.1016/j.canlet.2020.07.034. Epub 2020 Jul 31.
6
Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.重组蛋氨酸酶联合顺铂对裸鼠人结肠癌肿瘤的疗效。
Clin Cancer Res. 1999 Aug;5(8):2157-63.
7
Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells.与正常细胞相比,雷帕霉素与蛋氨酸酶联合对癌细胞的选择性协同作用。
Anticancer Res. 2024 Mar;44(3):929-933. doi: 10.21873/anticanres.16887.
8
DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts.DNA 结合药物 trabectedin 联合重组甲硫氨酸酶协同降低纤维肉瘤细胞活力并诱导核碎裂,但对正常成纤维细胞无协同作用。
Anticancer Res. 2024 Jun;44(6):2359-2367. doi: 10.21873/anticanres.17043.
9
Methioninase Gene Therapy.甲硫氨酸酶基因疗法
Methods Mol Biol. 2019;1866:173-197. doi: 10.1007/978-1-4939-8796-2_14.
10
Deletion of Highly Sensitizes Osteosarcoma Cells to Methionine Restriction With Recombinant Methioninase.缺失高度敏感骨肉瘤细胞对蛋氨酸限制与重组蛋氨酸酶。
Cancer Genomics Proteomics. 2022 May-Jun;19(3):299-304. doi: 10.21873/cgp.20321.

引用本文的文献

1
Eradication of Extensive Lymph-Node, Bone and Pleural Metastases of a Breast-Cancer Patient Treated With Radiation, Immunotherapy and Oral Recombinant Methioninase.放疗、免疫疗法及口服重组蛋氨酸酶治疗乳腺癌患者广泛淋巴结、骨及胸膜转移灶的清除
Cancer Diagn Progn. 2025 Sep 1;5(5):614-619. doi: 10.21873/cdp.10476. eCollection 2025 Sep-Oct.
2
Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential.癌症中的甲硫氨酸依赖性与限制:探索致病功能和治疗潜力
Pharmaceuticals (Basel). 2025 Apr 28;18(5):640. doi: 10.3390/ph18050640.
3
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice.
经筛选获得对艾日布林具有超强抗性的HT1080人纤维肉瘤细胞变得更具恶性,并且在裸鼠中,蛋氨酸限制与艾日布林联合使用可协同抑制其生长。
In Vivo. 2025 May-Jun;39(3):1275-1282. doi: 10.21873/invivo.13931.
4
HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine Restriction.获得性曲贝替定耐药的HT1080纤维肉瘤:恶性程度增加但对蛋氨酸限制持续敏感。
In Vivo. 2025 Mar-Apr;39(2):683-690. doi: 10.21873/invivo.13872.
5
Engineered Methioninase-expressing Tumor-targeting A1-R Inhibits Syngeneic-Cancer Mouse Models by Depleting Tumor Methionine.工程化表达甲硫氨酸酶的肿瘤靶向A1-R通过消耗肿瘤甲硫氨酸抑制同基因癌症小鼠模型。
Cancer Genomics Proteomics. 2025 Mar-Apr;22(2):247-257. doi: 10.21873/cgp.20499.
6
Targeting Methionine Addiction of Osteosarcoma with Methionine Restriction to Overcome Drug Resistance: A New Paradigm for a Recalcitrant Disease.通过限制甲硫氨酸靶向骨肉瘤的甲硫氨酸成瘾以克服耐药性:一种针对难治性疾病的新范式
Cancers (Basel). 2025 Feb 3;17(3):506. doi: 10.3390/cancers17030506.
7
Nutrient control of splice site selection contributes to methionine addiction of cancer.剪接位点选择的营养控制促成了癌症的甲硫氨酸成瘾。
Mol Metab. 2025 Mar;93:102103. doi: 10.1016/j.molmet.2025.102103. Epub 2025 Jan 23.
8
Epigenetic Regulation of Stromal and Immune Cells and Therapeutic Targets in the Tumor Microenvironment.肿瘤微环境中基质细胞和免疫细胞的表观遗传调控及治疗靶点
Biomolecules. 2025 Jan 6;15(1):71. doi: 10.3390/biom15010071.
9
Prostate Cancer Patient With Lymph-node Metastasis Treated Only With Methionine Restriction Has Stable Disease for Two Years Demonstrated With PET/CT and PSMA-PET Scanning and PSA Testing.仅接受蛋氨酸限制治疗的前列腺癌伴淋巴结转移患者,经PET/CT、PSMA-PET扫描及PSA检测显示,疾病稳定两年。
Cancer Diagn Progn. 2025 Jan 3;5(1):27-31. doi: 10.21873/cdp.10408. eCollection 2025 Jan-Feb.
10
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease.表达c-MYC且获得吉西他滨耐药性的纤维肉瘤细胞对重组蛋氨酸酶仍敏感:一种针对难治性疾病的潜在临床策略。
Cancer Diagn Progn. 2025 Jan 3;5(1):8-14. doi: 10.21873/cdp.10405. eCollection 2025 Jan-Feb.